Supplementary Table 1. Baseline Demographics and Characteristics of Japanese Patients in the Maintenance Study

Variable	Placebo (n = 5)[a]	Placebo (n = 6)[b]	Filgotinib 100 mg (n = 14)[c]	Placebo (n = 9)[d]	Filgotinib 200 mg (n = 20)[e]
Age (yr), mean ± SD	51.0 ± 15.0	45.0 ± 12.5	39.0 ± 13.3	46.0 ± 15.9	50.0 ± 15.8
Female sex	2 (40.0)	2 (33.3)	5 (35.7)	5 (55.6)	9 (45.0)
Body weight (kg), median (Q1–Q3)	58.8 (58.6–62.5)	60.8 (58.0–67.5)	58.2 (54.9–70.6)	55.9 (52.2–58.2)	60.2 (48.2–63.2)
BMI (kg/m^2), median (Q1–Q3)	22.1 (20.9–22.2)	22.3 (18.9–23.6)	20.7 (20.1–24.8)	22.5 (20.0–23.5)	22.2 (19.3–22.9)
Smoking status					
Former	3 (60.0)	3 (50.0)	6 (42.9)	3 (33.3)	10 (50.0)
Current	0	1 (16.7)	3 (21.4)	0	1 (5.0)
Never	2 (40.0)	2 (33.3)	5 (35.7)	6 (66.7)	9 (45.0)
Duration of UC (yr), mean ± SD	14.5 ± 13.7	15.2 ± 14.0	6.9 ± 4.9	9.8 ± 9.0	7.5 ± 6.5
Induction study A	3 (60.0)	2 (33.3)	7 (50.0)	4 (44.4)	7 (35.0)
Induction study B	2 (40.0)	4 (66.7)	7 (50.0)	5 (55.6)	13 (65.0)
C-reactive protein (mg/L), mean ± SD	0.71 ± 0.79	0.29 ± 0.17	4.34 ± 9.57	0.64 ± 0.69	0.76 ± 1.19
Fecal calprotectin (μg/g), mean ± SD	110.0 ± 150.4	489.0 ± 812.7	1,111.0 ± 1,938.9	1,008.0 ± 2,632.0	830.0 ± 1,527.5
Concomitant use of systemic corticosteroids[f]	1 (20.0)	1 (16.7)	5 (35.7)	3 (33.3)	7 (35.0)
Concomitant use of immunosuppressants[f,g]	2 (40.0)	2 (33.3)	5 (35.7)	2 (22.2)	4 (20.0)
Concomitant use of systemic corticosteroids and immunosuppressants	1 (20.0)	0	1 (7.1)	1 (11.1)	2 (10.0)
Prednisone-equivalent dose (mg/day), median (Q1–Q3)	17.5 (5.0–30.0)	17.5 (17.5–17.5)	10.0 (10.0–15.0)	7.5 (3.0–15.0)	10.0 (5.0–15.0)
Concomitant use of 5-ASA	5 (100.0)	6 (100.0)	9 (64.3)	8 (88.9)	13 (65.0)
Number of prior biologic agents used					
0	3 (60.0)	2 (33.3)	7 (50.0)	4 (44.4)	7 (35.0)
1	1 (20.0)	1 (16.7)	2 (14.3)	2 (22.2)	6 (30.0)
2	0	3 (50.0)	5 (35.7)	2 (22.2)	4 (20.0)
≥ 3	1 (20.0)	0	0	1 (11.1)	3 (15.0)
Prior use of at least one TNF antagonist	2 (40.0)	4 (66.7)	7 (50.0)	5 (55.6)	13 (65.0)
Prior use of vedolizumab	1 (20.0)	0	2 (14.3)	0	1 (5.0)
Prior use of at least one TNF antagonist and vedolizumab	1 (20.0)	0	2 (14.3)	0	1 (5.0)
Prior failure of at least one TNF antagonist	2 (40.0)	3 (50.0)	7 (50.0)	4 (44.4)	11 (55.0)
Prior failure of vedolizumab	0	0	1 (7.1)	0	0

Values are presented as number (%) unless otherwise indicated.
[a]Patients who responded with placebo in the induction studies and continued to receive placebo in the maintenance study.
[b]Patients who responded with filgotinib 100 mg in the induction studies and were randomly assigned to placebo in the maintenance study.
[c]Patients who responded with filgotinib 100 mg in the induction studies and were randomly assigned to filgotinib 100 mg in the maintenance study.
[d]Patients who responded with filgotinib 200 mg in the induction studies and were randomly assigned to placebo in the maintenance study.
[e]Patients who responded with filgotinib 200 mg in the induction studies and were randomly assigned to filgotinib 200 mg in the maintenance study.
[f]Corticosteroids or immunosuppressants, but not both.
[g]6-Mercaptopurine, azathioprine, and methotrexate.
SD, standard deviation; Q1, first quartile; Q3, third quartile; BMI, body mass index; UC, ulcerative colitis; 5-ASA, 5-aminosalicylates; TNF, tumor necrosis factor.

https://doi.org/10.5217/ir.2021.00143 • Intest Res 2023;21(1):110-125